Navigation Links
ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan
Date:7/8/2009

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time.

"It is a privilege to have been invited to speak at this prestigious gathering of thought leaders involved in the search for innovative treatments in inflammatory disease," said Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer. "With recent regulatory approvals and clinical trial successes of chemokine-based therapeutics, this underscores the enthusiasm and promise of developing drugs that selectively inhibit specific chemokine and chemoattractant receptors in the treatment of inflammatory diseases."

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading ... Word(TM) Online(TM), which enables sleep physicians to create and edit their interpretation reports. ... and provides a familiar interface that does not require additional training to use. ...
(Date:4/28/2017)... Grants Pass, OR (PRWEB) , ... April 28, ... ... Adetutu Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to ... to bookmark and read organized content on topics such as home care (generally) as ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology: